Strategic Growth Outlook for Indian CDMOs: Leveraging GLP-1 Patent Expiries and the Next Wave of Off-Patent Drugs"

The impending patent cliff for GLP-1 drugs (e.g., semaglutide, tirzepatide) unlocks a massive generics opportunity for Indian CDMOs. This analysis assesses the multi-billion dollar market potential in producing these complex APIs and formulations. It evaluates India's competitive edge in cost-effective chemical synthesis and scaling complex peptide manufacturing. Strategic pathways include investing in high-potency API (HPAPI) handling and advanced delivery systems like pens. Success hinges on securing first-to-file positions and forging partnerships for authorized generics. The project details the capital investment required for specialized infrastructure and technology transfer. It also analyzes the threat from innovator lifecycle management and regulatory hurdles. The focus is on capturing value in a high-growth segment beyond traditional small molecules. This demand strengthens India's position in the global biopharma supply chain. Investment potential is significant for firms with the technical capability and financial strength to compete.